Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops
4/9 05:14
(RTTNews) - Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S (ASND), has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma plc (RPRX) based on U.S. net sales of YORVIPATH....